# Natriuretic Peptides and Metabolic Risk in Obesity

> **NCT02642523** · EARLY_PHASE1 · WITHDRAWN · sponsor: **Vanderbilt University Medical Center**

## Conditions studied

- Obesity
- Hyperinsulinemia

## Interventions

- **DRUG:** Nesiritide
- **DRUG:** Insulin
- **OTHER:** Saline

## Key facts

- **NCT ID:** NCT02642523
- **Lead sponsor:** Vanderbilt University Medical Center
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** —
- **Primary completion:** 2017-02
- **Final completion:** 2017-02
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Preliminary data run on rat samples showed that this study question and design would not produce conclusive results. The PI decided not to carry out the study.
- **Last updated:** 2017-11-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02642523

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02642523, "Natriuretic Peptides and Metabolic Risk in Obesity". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT02642523. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*